### **Supporting Information for**

## Catalytic Asymmetric Direct Mannich Reaction of Glycine Schiff Bases with α-Amido Sulfones as Precursors of Enolizable Aliphatic Imines

Elier Hernando, Ramón Gómez Arrayás\* and Juan C. Carretero\*

Departamento de Química Orgánica. Facultad de Ciencias. Universidad Autónoma de Madrid. Cantoblanco. 28049 Madrid, Spain.

#### Contents

1.	Experimental section	S-2
2.	Determination of the absolute and relative configuration S	3-25
3.	Base and solvent screening	5-26
4.	Chiral ligand screening	S-27
5.	NMR spectra	S-28

#### **1. Experimental Section**

#### 1.1. General methods

All the reactions were carried out in anhydrous solvents and under inert atmosphere. Melting points were measured in open-end capillary tubes. NMR spectra were recorded at 300 MHz (<sup>1</sup>H), 75 MHz (<sup>13</sup>C), at room temperature in CDCl<sub>3</sub> [calibrated at 7.28 ppm (<sup>1</sup>H) and 77.0 ppm (<sup>13</sup>C)] and acetone [calibrated at 2.05 (<sup>1</sup>H) and 206.7. (<sup>13</sup>C)] unless indicated. Mass spectra (MS) were determined at an ionizing voltage of 70 eV. The sodium and/or methoxy adduct of the molecular ion were detected in most of mass spectra due to the presence of Na<sup>+</sup> as the ionization source or MeOH as solvent. HPLC experiments were conducted using Daicel Chiralpak AD and IA columns. Flash column chromatography was performed using silica gel Merk-60 (230-400 mesh). Iminoesters **2a-d** were prepared according to reported literature procedures.<sup>1</sup> The racemic products were prepared under identical conditions at room temperature, but using 1,1′-Bis(diphenyl-phosphino)ferrocene (dppf), (10 mol%) instead of (*R*)-Fesulphos as the ligand.<sup>2</sup>

#### **1.2.** Synthesis of $\alpha$ -Amido sulfones

General procedure  $A^3$ : To a solution of sulfonamide (1.0 equiv) and TolSO<sub>2</sub>Na (1.2 equiv) in a 1:1 mixture of formic acid and H<sub>2</sub>O (30 mL), cooled to 0 °C, was added the corresponding aliphatic aldehyde (1.0 equiv). The solution was warmed up to room temperature and stirred for 24 h, whereupon a white solid precipitated. The white powder was successively washed with water and pentane, and then air-dried to give the  $\alpha$ -amido sulfone.

General procedure  $B^4$ : To a solution of *tert*-Butyl carbamate (1.0 equiv) and TolSO<sub>2</sub>Na (2.0 equiv) in a 1:2 mixture of MeOH/H<sub>2</sub>O (20 mL), cooled to 0 °C, was successively added the corresponding aliphatic aldehyde (1.5 equiv) and formic acid (0.41 mL). The solution was warmed up to room temperature and stirred for 24 h, whereupon a white solid precipitated. The white powder was successively washed with water, diethyl ether and pentane, to give the corresponding  $\alpha$ -amido sulfone.

 <sup>(</sup>a) S. Cabrera, R. Gómez Arrayás, J. C. Carretero, J. Am. Chem. Soc. 2005, 127, 16394; (b) T. Llamas, R. Gómez Arrayás. J. C. Carretero, Org. Lett. 2006, 8, 1795; (c) D. G. Brenner, K. M. Cavolowsky, K. L. Shepard, J. Het. Chem. 1995, 22, 805; (d) M. J. O'Donnell, R. L. Polt. J. Org. Chem. 1982, 47, 2663.

<sup>2. 1,1&#</sup>x27;-Bis(diphenyl-phosphino)ferrocene (dppf) typically provides lower yields and much poorer *syn*-diastereoselectivities than the (*R*)-Fesulphos ligand.

<sup>3.</sup> F. Chemla, V. Hebbe, J-F. Normandt, Synthesis, 2000, 1, 75.

<sup>4.</sup> H. Zhang, S. Syed, Carlos F. Barbas III, Org. Lett. 2010, 12, 708.

#### 4-Methyl-N-(1-tosylethyl)benzenesulfonamide (1a). Following the general procedure



A, the reaction of acetaldehyde (0.56 mL, 10.0 mmol) with *p*-toluensulfonamide (1.71 g, 10.0 mmol) and TolSO<sub>2</sub>Na (1.97 g, 12.0 mmol), afforded **1a** as a white solid; yield: 3.18 g (90%); m.p: 114-116 °C. <sup>1</sup>H HMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.77 (d, *J* = 8.1 Hz,

2H); 7,58 (d, J = 8.1 Hz, 2H); 7.33 (d, J = 7.9 Hz, 2H); 7.23 (d, J = 7.9 Hz, 2H); 5.78 (d, J = 9.8 Hz, 1H); 4.47-4.45 (m, 1H); 2.48 (s, 3H); 2.44 (s, 3H); 1.49 (d, J = 6.8 Hz. 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.4; 143.4; 137.3; 132.3; 129.7; 129.6; 126.8; 69.4; 21.8; 21.6; 14.3. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-*p*TolSO<sub>2</sub>+H): calculated C<sub>9</sub>H<sub>12</sub>NO<sub>2</sub>S: 198.0590; Found: 198.0576. (M<sup>+</sup>-*p*TolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>10</sub>H<sub>115</sub>NNaO<sub>3</sub>S: 252.0670; Found: 252.0656. Elemental analysis: calculated C<sub>16</sub>H<sub>19</sub>NO<sub>4</sub>S<sub>2</sub>: C, 54.37; H, 5.42; N, 3.96; S, 18.14. Found: C, 54.48; H; 5.37; N, 3.92; S, 18.08.

tert-Butyl-(1-tosylethyl)carbamate (1b). Following procedure B, tert-butyl carbamate



(0.69 g, 5.94 mmol) and TolSO<sub>2</sub>Na (2.17 g, 11.88 mmol) reacted with acetaldehyde (0.50 mL, 8.91 mmol) to afford **1b** as a white solid; yield: 1.41 g (80%); m.p: 110-111 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.83 (d, *J* = 8.1 Hz, 2H); 7.37 (d, *J* = 7.7 Hz, 2H);

5.14-4.89 (m, 2H); 2.46 (s, 3H); 1.64 (d, J = 6.6 Hz, 3H); 1.26 (s, 9H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 153.6; 144.8; 133.6; 129.6; 129.4; 80.4; 66.9; 27.9; 21.5; 12.8. HRMS (ESI<sup>+</sup>) (M+Na<sup>+</sup>): calculated C<sub>14</sub>H<sub>21</sub>NNaO<sub>4</sub>S: 322.1083 Found: 322.1089. (2M+Na<sup>+</sup>): calculated C<sub>28</sub>H<sub>42</sub>N<sub>2</sub>NaO<sub>8</sub>S<sub>2</sub>: 621.2280; Found: 621.2276.

4-Nitro-N-(1-tosylethyl)benzenesulfonamide (1c). Following the general procedure A,



the reaction of acetaldehyde (0.22 mL, 3.87 mmol) with 4nitrobenzenesulfonamide (0.52 g, 2.58 mmol) and TolSO<sub>2</sub>Na (0.93 g, 5.17 mmol), afforded **1c** as a white solid; yield: 0.70 g (71%); m.p: 135-137 °C. <sup>1</sup>H-NMR (300 MHz, Acetone),  $\delta$ 

(ppm): 8.36 (d, J = 8.9 Hz, 2H); 8.01 (d, J = 8.8 Hz, 2H); 7.82 (d, J = 9.4 Hz, 1H); 7.68 (d, J = 8.2, 2H); 7.36 (d, J = 7.9 Hz, 2H); 4.85 (dd, J = 10.0 Hz, J = 6.8 Hz, 1H); 2.42 (s, 3H); 1.46 (d, J = 6.6 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, Acetone),  $\delta$  (ppm): 150.9; 147.6; 146.0; 134.2; 130.5; 130.4; 129.0; 125.2; 70.3; 21.5; 14.9. HRMS (ESI<sup>+</sup>) (M+Na<sup>+</sup>): calculated C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>NaO<sub>6</sub>S<sub>2</sub>: 407.0342; Found: 407.0332. (2M+Na<sup>+</sup>): calculated C<sub>30</sub>H<sub>32</sub>N<sub>4</sub>Na<sub>2</sub>O<sub>12</sub>S<sub>4</sub>: 791.0747; Found: 791.0822.

#### N-(1-Tosylethyl)naphthalene-2-sulfonamide (1d). Following the general procedure A,



the reaction of acetaldehyde (0.20 mL, 3.62 mmol) with naphthalene-2-sulfonamide (0.50 g, 2.41 mmol) and TolSO<sub>2</sub>Na (0.86 g, 4.82 mmol) afforded **1d** as a white solid; yield: 0.63 g (67%); m.p: 118-119 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 8.46-8.39 (m, 1H); 8.11-8.03 (m, 2H); 7.99-

7.93 (m, 1H); 7.78-7.59 (m, 2H); 7.50-7.40 (m, 3H); 6.90 (d, J = 8.1 Hz, 2H); 5.44-5.25 (m, 1H); 4.67-4.49 (m, 1H); 2.33 (s, 3H); 1.56 (d, J = 6.8 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 144.8; 134.6; 134.4; 134.1; 132.1; 129.2; 129.0; 128.9; 128.6; 127.7; 127.0; 124.2; 124.0; 69.4; 21.7; 14.9. HRMS (ESI<sup>+</sup>) (2M+Na<sup>+</sup>): calculated C<sub>19</sub>H<sub>19</sub>NNaO<sub>4</sub>S<sub>2</sub>: 412.0647; Found: 412.0648. (2M+Na<sup>+</sup>): calculated C<sub>38</sub>H<sub>38</sub>N<sub>2</sub>NaO<sub>8</sub>S<sub>4</sub>: 801.1409; Found: 801.1448.

**4-Methyl-***N*-(1-tosylpropyl)benzenesulfonamide (10): Following the general procedure A, the reaction of propionaldehyde (0.73 mL, 10.0 mmol) with *p*-toluenesulfonamide (1.71 g, 10.0 mmol) and TolSO<sub>2</sub>Na (1.97 g, 12.0 mmol) afforded **10** as a white solid; yield 2.84 g (77%); m.p: 118–120 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.73 (d, *J* = 8.3 Hz, 2H); 7.58 (d, *J* = 8.5 Hz, 2H); 7.31 (d, *J* = 8.5 Hz, 2H); 7.23 (d,

J = 7.9 Hz, 2H); 5.33 (d, J = 9.7 Hz, 1H), 4.43 (dt, J = 4.0 Hz, J = 10.0, 1H); 2.48 (s, 3H); 2.45 (s, 3H); 2.37-2.25 (m, 1H); 1.76-1.74 (m, 1H); 0.91 (t, J = 7.4 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.2; 143.6; 137.9; 132.9; 129.7; 129.6; 129.6; 126.7; 75.0; 21.9; 21.8; 21.6; 9.8. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-*p*TolSO<sub>2</sub>+H): calculated C<sub>10</sub>H<sub>14</sub>NO<sub>2</sub>S: 212.0747. Found: 212.0742. (M<sup>+</sup>-*p*TolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>11</sub>H<sub>17</sub>NNaO<sub>3</sub>S: 266.0827; Found: 266.0837.

4-Methyl-N-(1-tosylbutyl)benzenesulfonamide (11). Following the general procedure



A, the reaction of butyraldehyde (0.90 mL, 10.0 mmol) with *p*-toluenesulfonamide (1.71 g, 10.0 mmol) and TolSO<sub>2</sub>Na (1.97 g, 12.0 mmol) afforded **11** as a white solid; yield: 2.58 g (67%); m.p: 119–120 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.70 (d, *J* = 8.3 Hz, 2H); 7.57 (d, *J* = 8.3 Hz, 2H); 7.30 (d, *J* = 8.1 Hz, 2H); 7.23 (d,

J = 8.1 Hz, 2H); 5.35 (d, J = 10.4 Hz, 1H), 4.61 (dt, J = 10.2 Hz, J = 3.6, 1H); 2.47 (s, 3H); 2.45 (s, 3H); 2.16-2.13 (m, 1H); 1.69-1.67 (m, 1H); 1.41-1.39 (m, 1H); 1.27-1.25 (m, 1H); 0.86 (t, J = 7.2 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.3; 143.6; 137.9; 132.8; 129.7; 129.6; 126.8; 126.5; 73.7; 30.4; 21.8; 21.6; 18.5; 13.5. HRMS

 $(ESI^{+})$   $(M^{+}-pTolSO_{2}+H)$ :  $C_{11}H_{16}NO_{2}S$ : 226.0902. Found: 226.0895.  $(M^{+}-pTolSO_{2}+Na+MeO^{-})$ : calculated  $C_{12}H_{19}NNaO_{3}S$ : 280.0983; Found: 280.0983.

4-Methyl-N-(1-tosyloctyl)benzenesulfonamide (12). Following the general procedure



A, the reaction of octanal (1.5 mL, 9.59 mmol) with *p*-toluenesulfonamide (1.67 g, 9.59 mmol) and TolSO<sub>2</sub>Na (2.09 g, 11.51 mmol) afforded **12** as a white solid; yield: 3.30 g (76%); m.p: 112–113 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.76 (d, J = 8.3 Hz, 2H); 7.60 (d, J = 8.3 Hz, 2H); 7.35 (d, J = 8.1 Hz,

2H); 7.23 (d, J = 8.3 Hz, 2H); 5.51 (d, J = 9.8 Hz, 1H); 4.57 (dt, J = 10.2 Hz, J = 3.6 Hz, 1H); 2.48 (s, 3H); 2.44 (s, 3H); 2.17-2.14 (m, 1H); 1.69-1.66 (m, 1H); 1.40-1.00 (m, 10 H); 0.89 (t, J = 6.8 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.3; 143.6; 137.9; 132.8; 129.7; 129.6; 126.8; 73.8; 31.5; 28.9; 28.8; 28.2; 25.1; 22.6; 21.8; 21.5; 14.0. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-pTolSO<sub>2</sub>+H): calculated C<sub>15</sub>H<sub>24</sub>NO<sub>2</sub>S: 282.1522; Found: 282.1520. (M<sup>+</sup>-pTolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>16</sub>H<sub>27</sub>NNaO<sub>3</sub>S: 336.1616; Found: 336.1620.

4-Methyl-N-(3-methyl-1-tosylbutyl)benzenesulfonamide (13). Following the general



procedure A, the reaction of 3-methyl-butyraldehyde (1.10 mL, 10.0 mmol) with *p*-toluenesulfonamide (1.71 g, 10.0 mmol) and TolSO<sub>2</sub>Na (1.97 g, 12.0 mmol) afforded **13** as a white solid; yield: 3.40 g (84%). m.p: 122–123 °C; <sup>1</sup>H-NMR (300 MHz,

CDCl<sub>3</sub>),  $\delta$  (ppm): 7.58 (d, J = 8.3 Hz, 2H); 7,47 (d, J = 8.3 Hz, 2H); 7.21 (d, J = 7.9 Hz, 2H); 7.14 (d, J = 7.9 Hz, 2H); 4.84 (d, J = 9.4 Hz, 1H); 4.61 (dt, J = 10.5 Hz, J = 3.7 Hz, 1H); 2.37 (s, 3H); 2.35 (s, 3H); 1.90-1.87 (m, 1H); 1.53-1.51 (m, 2H); 0.82 (d, J = 6.4 Hz, 3H); 0.77 (d, J = 6.4 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.3; 143.6; 138.0; 132.74; 129.7; 129.7; 129.5; 126.8; 72.6; 37.4; 24.1; 23.3; 21.8; 21.6; 21.1. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-pTolSO<sub>2</sub>+H): calculated C<sub>12</sub>H<sub>18</sub>NO<sub>2</sub>S: 240.1058. Found: 240.1056. (M<sup>+</sup>-pTolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>13</sub>H<sub>21</sub>NNaO<sub>3</sub>S: 294.1140; Found: 294.1126. Elemental analysis: calculated C<sub>19</sub>H<sub>25</sub>NO<sub>4</sub>S<sub>2</sub>: C, 57.69; H, 6.37; N, 3.54; S, 16.21. Found: C, 57.64; H; 6.31; N, 3.49; S, 16.24.

N-(2-Ethyl-1-tosylbutyl)-4-methylbenzenesulfonamide (14). Following the general



procedure A, the reaction of 2-ethylbutanal (1.0 mL, 8.83 mmol) with *p*-toluenesulfonamide (1.51 g, 8.83 mmol) and TolSO<sub>2</sub>Na (1.89 g, 10.61 mmol) afforded **14** as a white solid; yield: 1.10 g (31%); m.p: 56-57 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm):

7.61 (d, *J* = 8.3 Hz, 2H); 7.44 (d, *J* = 8.3 Hz, 2H); 7.24-7.16 (m, 2H); 7.11 (d, *J* = 8.1 Hz, 2H); 5.14 (d, *J* = 10.6 Hz, 1H); 4.60 (dd, *J* = 10.6 Hz, *J* = 1.9 Hz, 1H); 2.37 (s, 3H);

2.34 (s, 3H); 2.03-1.92 (m, 1H); 1.82-1.68 (m, 1H); 1.51-1.37 (m, 1H); 1.11-0.93 (m, 1H); 0.92-0.83 (t, J = 7.2 Hz, 1H); 0.83-0.74 (t, J = 6.8 Hz, 1H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.0; 143.6; 138.1; 134.3; 129.7; 129.5; 129.2; 126.6; 74.2; 41.5; 22.8; 22.0; 21.7; 21.6; 11.9; 11.7. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-pTolSO<sub>2</sub>+H): calculated C<sub>13</sub>H<sub>20</sub>NO<sub>2</sub>S: 254.1215. Found: 254.1210. (M<sup>+</sup>-pTolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>14</sub>H<sub>23</sub>NNaO<sub>3</sub>S: 308.1290 Found: 308.1283.

N-[Cyclopentyl(tosyl)methyl]-4-methylbenzenesulfonamide (15). Following the



general procedure A, the reaction of cyclopentanecarboxaldehyde (0.50 mL, 4.54 mmol) with *p*-toluenesulfonamide (0.79 g, 4.54 mmol) and TolSO<sub>2</sub>Na (1.0 g, 5.45 mmol) afforded **15** as a white solid; yield: 1.48 g (80%); m.p: 111–112 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.69 (d, *J* = 8.3 Hz, 2H); 7.52(d, *J* = 8.1 Hz,

2H); 7.27 (d, J = 7.9 Hz, 2H); 7.21 (d, J = 8.1 Hz, 2H); 5.19 (d, J = 10.6 Hz, 1H); 4.73 (dd, J = 10.3 Hz, J = 5.1 Hz, 1H); 2.67-2.64 (m, 1H); 2.47 (s, 3H); 2.45 (s, 3H); 1.89-1.85 (m, 2H), 1.57-1.54 (m, 4H), 1.30-1.26 (m, 2H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.0; 143.5; 138.1; 133.8; 129,7; 129.5; 129.4; 126.7; 38.9; 30.2; 27.9; 24.9; 24.7; 21.8; 21.5. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-pTolSO<sub>2</sub>+H): calculated C<sub>13</sub>H<sub>18</sub>NO<sub>2</sub>S: 252.1052. Found: 252.1058. (M<sup>+</sup>-pTolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>14</sub>H<sub>21</sub>NNaO<sub>3</sub>S: 306.1140. Found: 306.1140. Elemental analysis: calculated C<sub>20</sub>H<sub>25</sub>NO<sub>4</sub>S<sub>2</sub>: C, 58.94; H, 6.18; N, 3.44; S, 15.74. Found: C, 58.56; H; 6.11; N, 3.38; S, 15.50.

N-[Cyclohexyl(tosyl)methyl]-4-methylbenzenesulfonamide (16). Following the



general procedure A, the reaction of cyclohexanecarboxaldehyde (0.93 mL, 10.0 mmol) with *p*-toluenesulfonamide (1.71 g, 10.0 mmol) and TolSO<sub>2</sub>Na (1.97 g, 12.0 mmol) afforded **16** as a white solid; yield: 3.01 g (71%); m.p: 101–103 °C. <sup>1</sup>H-NMR (300 MHz,

CDCl<sub>3</sub>),  $\delta$  (ppm): 7.69 (d, J = 8.3 Hz, 2H); 7.48 (d, J = 8.3 Hz, 2H); 7.25 (d, J = 8.1 Hz, 2H); 7.20 (d, J = 7.9 Hz, 2H); 5.28 (d, J = 10.6 Hz, 1H); 4.50 (dd, J = 10.7 Hz, J = 2.8 Hz, 1H); 2.47 (s, 3H); 2.45 (s, 3H); 2.43-2.41 (m, 1H); 2.06-2.03 (m, 1H); 1.76-1.72 (m, 4H); 1.23-1.19 (m, 2H); 1.07-1.03 (m, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.0; 143.4; 138.2; 134.2; 129.7; 129.5; 129.3; 126.7; 37.4; 31.0; 27.2; 26.2; 25.7; 25.6; 21.8; 21.6. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-*p*TolSO<sub>2</sub>+H): calculated C<sub>14</sub>H<sub>20</sub>NO<sub>2</sub>S: 266.1215. Found: 266.1210. (M<sup>+</sup>-*p*TolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>15</sub>H<sub>23</sub>NNaO<sub>3</sub>S: 320.1296; Found: 320.1278.

#### 4-Methyl-N-(3-phenyl-1-tosylpropyl)benzenesulfonamide (17). Following the



general procedure A, the reaction of hydrocinnamaldehyde (1.46 mL, 10.0 mmol) with *p*-toluenesulfonamide (1.71 g, 10.0 mmol) and TolSO<sub>2</sub>Na (1.97 g, 12.0 mmol) afforded **17** as a white solid; yield: 3.91 g (88%); m.p: 127–129 °C. <sup>1</sup>H-NMR

(300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.60 (d, J = 8.3 Hz, 2H); 7,46 (d, J = 8.5 Hz, 2H); 7.23-7.15 (m, 7H); 6.96 (d, J = 6.7 Hz, 2H); 5.33 (s, 1H), 4.50 (dt, J = 10.3 Hz, J = 4.1 Hz, 1H); 2.68-2.39 (m, 3H); 2.36 (s, 3H); 2.33 (s, 3H); 2.01-1.81 (m, 1H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.4.; 143.8; 139.8; 137.8; 132.7; 129.8; 129.7; 128.6; 128.4; 126.8; 126.4; 73.2; 31.3; 30.3; 21.8; 21.6. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-pTolSO<sub>2</sub>+H): calculated C<sub>16</sub>H<sub>18</sub>NO<sub>2</sub>S: 288.1058. Found: 288.1047. (M<sup>+</sup>-pTolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>17</sub>H<sub>21</sub>NNaO<sub>3</sub>S: 342.1140; Found: 342.1134.

(E)-4-Methyl-N-(1-tosylhept-4-enyl)benzenesulfonamide (18). Following the general



procedure A, the reaction of *trans*-4-hepten-1-al (1.50 mL, 11.37 mmol) with *p*-toluenesulfonamide (1.97 g, 11.37 mmol) and TolSO<sub>2</sub>Na (2.48 g, 13.64 mmol) afforded **18** as a white solid; yield: 1.48 g (30%); m.p:

103–105 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.73 (d, J = 8.1 Hz, 2H); 7.60 (d, J = 8.3 Hz, 2H); 7.33 (d, J = 8.1 Hz, 2H); 7.25 (d, J = 8.1 Hz, 2H); 5.42-5.39 (m, 1H); 5.23-5.20 (m, 2H); 4.58 (dt, J = 9.6 Hz, J = 4.1 Hz, 1H); 2.49 (s, 3H); 2.45 (s, 3H); 2.30-2.17 (m, 1H); 2.15-1.59 (m, 4H); 1.58-1.56 (m, 1H); 0.94 (t, J = 7.3 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.3; 143.7; 137.9; 133.8; 132.8; 129.8; 129.7; 129.6; 126.8; 126.1; 73.4; 28.7; 23.0; 21.8; 21.5; 20.5; 14.1. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-pTolSO<sub>2</sub>+H): calculated C<sub>14</sub>H<sub>20</sub>NO<sub>2</sub>S: 266.1215. Found: 266.1215. (M<sup>+</sup>-pTolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>15</sub>H<sub>23</sub>NNaO<sub>3</sub>S: 320.1296; Found: 320.1275.

N-[2-(Benzyloxy)-1-tosylethyl]-4-methylbenzenesulfonamide (19). Following the general procedure A, the reaction of 2-(benzyloxy)acetaldehyde (0.40 mL, 2.85 mmol) with*p*-toluenesulfonamide (0.48 g, 2.85 mmol) and TolSO<sub>2</sub>Na (0.56 g, 3.42 mmol) afforded**19**as a white solid; yield:

0.91 g (70%); m.p: 118-120 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.71-7.66 (m, 2H); 7.65-7.59 (m, 2H); 7.38-7.32 (m, 3H); 7.28-7.23 (m, 3H) ; 7.23-7.17 (m, 3H); 5.52 (d, *J* = 10.2Hz, 1H); 4.71-4.63 (m, 1H); 4.96 (dt, *J* = 11.8 Hz, *J* = 7.7 Hz, 2H); 4.12 (dd, *J* = 10.8 Hz, *J* = 3.1 Hz, 1H); 3.64 (dd, *J* = 10.7 Hz, *J* = 4.3 Hz, 1H); 2.47 (s, 3H); 2.45 (s, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.3; 143.9; 137.3; 136.6; 133.3; 129.7;

129.6; 129.6; 128.4; 128.0; 127.8; 127.0; 73.7; 72.7; 65.9; 21.7; 21.6. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-pTolSO<sub>2</sub>+H): calculated  $C_{16}H_{18}NO_3S$ : 304.1007. Found: 304.1015. (M<sup>+</sup>-pTolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated  $C_{17}H_{21}NNaO_4S$ : 358.1083. Found: 358.1102.

**4-Methyl-***N***-(tosylmethyl)benzenesulfonamide (30).** Following the general procedure A, the reaction of formaldehyde (0.74 mL, 37% w/w aq. solution, 10.0 mmol) with *p*-toluenesulfonamide (1.71 g, 10.0 mmol) and TolSO<sub>2</sub>Na (1.97 g, 12.0 mmol) afforded **30** as a white solid; yield: 2.91 g (86%); m.p: 161–162 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.77 (d, *J* = 8.3 Hz, 2H); 7,62 (d, *J* = 8.3 Hz, 2H); 7.37 (d, *J* = 7.9 Hz, 2H); 7.32 (d, *J* = 7.9 Hz, 2H); 5.34 (t, *J* = 7.4 Hz, 1H), 4.37 (d, *J* = 7.1 Hz, 2H); 2.50 (s, 3H); 2.47 (s, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 145.7; 144.2; 136.8; 133.0; 130.0; 129.8; 129.1; 126.8; 63.5; 21.8; 21.6. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>-pTolSO<sub>2</sub>+H): calculated C<sub>8</sub>H<sub>10</sub>NO<sub>2</sub>S: 184.0426; Found: 184.0433. (M<sup>+</sup>-pTolSO<sub>2</sub>+Na+MeO<sup>-</sup>): calculated C<sub>9</sub>H<sub>13</sub>NNaO<sub>3</sub>S: 238.0514;

Found: 238.0501. Elemental analysis: calculated  $C_{15}H_{17}NO_4S_2$ : C, 53.08; H, 5.05; N, 4.13; S, 18.89. Found: C, 53.32; H; 5.05; N, 4.06; S, 18.64.

#### 1.3. General procedure for the asymmetric Mannich reaction



To a solution of (*R*)-Fesulphos (6.87 mg, 10 mol %) and Cu(CH<sub>3</sub>CN)<sub>4</sub>PF<sub>6</sub> (5.59 mg, 10 mol %) in THF (2 mL), under inert atmosphere and the optimum temperature (indicated in each entry), were successively added the corresponding glycine derivative (0,15 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.22 mmol) and the aliphatic  $\alpha$ -amido sulfone (0.19 mmol). The reaction mixture was stirred upon consumption of the starting material (TLC monitoring) and filtered through Celite. After evaporation of the solvent, the crude product was analyzed by <sup>1</sup>H NMR spectroscopy to determine the diastereomeric ratio and then purified by column chromatography on silica gel (the eluent is indicated for each case).

Products 6 and 20-29, were isolated as inseparable mixtures of *syn/anti* diastereomers, which were analyzed by chiral HPLC to determine enantioselectivity, as well as diastereoselectivity.

*Racemic Mannich reaction*: In spite of the high diastereo and enantioselectivities achieved with the Fesulphos ligand, very poor *syn/anti* mixtures were obtained following the general procedure using a combination of dppf [1,1'-Bis-(diphenylphosphino)-ferrocene] and Cu(CH<sub>3</sub>CN)<sub>4</sub>PF<sub>6</sub> as the catalyst.

#### (2S,3R)-Methyl-2-(diphenylmethyleneamino)-3-(4-methylphenylsulfonamido)-



**butanoate (3).** Following the general procedure, the reaction of methyl 2-[(diphenylmethylene)amino]acetate (2a) (38.0 mg, 0.15 mmol) with 4-methyl-*N*-(1-tosylethyl)benzenesulfonamide (1a) (69.0 mg, 0.19 mmol) in THF (2 mL) at rt for 5 h, afforded, after flash chromatography (*n*-hexane-EtOAc 6:1), *syn*-3 as a

yellow oil; yield: 35.1 mg (52%, *syn/anti* = 88:12). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.68 (d, J = 8.3 Hz, 2H); 7.57-7.53 (m, 2H); 7.39-7.32 (m, 4H); 7.30-7.24 (m, 2H); 7.22-7.16 (m, 2H); 7.03-6.91 (m, 2H); 5.56 (d, J = 9.0 Hz, 1H); 3.96-3.87 (m, 1H); 3.86 (d, J = 3.0 Hz, 1H); 3.31 (s, 3H); 2.34 (s, 3H); 1.06 (d, J = 6.0 Hz, 3H). *ee* = 93 %;  $[\alpha]_D^{25}$ : -14 (*c* = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak IA, *i*-PrOH/hexane

ee = 93%;  $[\alpha]_D$  : -14 (c = 1.0; CHCl<sub>3</sub>). HPLC: Dateel Chiralpak IA, *i*-PrOH/nexane 10/90, flow rate 1.0 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  <sub>syn</sub>: 15.7 min (2*R*,3*S*) and 21.5 min (2*S*,3*R*).



#### (2S,3R)-tert-Butyl-2-(diphenylmethyleneamino)-3-(4-methylphenylsulfonamido)-



**butanoate (4).** Following the general procedure, the reaction of methyl *tert*-butyl 2-(diphenylmethyleneamino)acetate **(2b)** (44.3 mg, 0.15 mmol) with **1a** (68.9 mg, 0.19 mmol) in THF (2 mL) at -20°C for 17 h, afforded, after flash chromatography (*n*-hexane-EtOAc 6:1), *syn-***4** as a yellow oil; yield: 29.5 mg (40%, *syn/anti* 

= 96:4). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>), δ (ppm): 7.69 (d, *J* = 8.1 Hz, 2H); 7.58-7.52 (m, 2H); 7.36-7.32 (m, 4H); 7.31-7.26 (m, 2H); 7.20-7.14 (m, 2H); 7.04-6.96 (m, 2H); 5.51 (d, *J* = 9.2 Hz, 1H); 3.99-3.87 (m, 1H); 3.75 (d, *J* = 2.2 Hz, 1H); 2.33 (s, 3H); 1.27 (s,

9H); 0.98 (d, *J* = 6.6 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>), δ (ppm): 172.3; 168.9; 142.8; 139.2; 138.9; 136.2; 130.7; 129.5; 128.8; 128.8; 128.6; 128.1; 127.4; 126.9; 82.0; 69.3; 52.1; 27.8; 21.5; 19.6.

*ee* = 97%;  $[\alpha]_D^{25}$ : -17 (*c* = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak IA, *i*-PrOH/hexane 4/96, flow rate 1.0 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  <sub>syn</sub>: 21.1 min (2*R*,3*S*) and 33.6 min (2*S*,3*R*).



(2S,3R)-tert-Butyl-2-{[bis(4-chlorophenyl)methylene]amino}-3-(4-methylphenyl-



sulfonamido)butanoate (5). Following the general procedure, the reaction of *tert*-butyl 2-[bis(4chlorophenyl)methyleneamino]acetate (2c) (54.6 mg, 0.15 mmol) with 1a (68.9 mg, 0.19 mmol) in THF (2 mL), at -20 °C for 17 h, afforded, after flash chromatography (n-hexane-EtOAc 6:1), syn-5 as a light yellow solid; yield: 52.2 mg (62%, svn/anti = >98:<2); m.p: 197-200 °C. <sup>1</sup>H-NMR (300

MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.68 (d, J = 8.3 Hz, 2H); 7.46 (d, J = 8.5 Hz, 2H); 7.33 (d, J = 8.4 Hz, 2H); 7.23 (d, J = 8.6 Hz, 2H); 7.18 (m, 2H); 6.94 (d, J = 8.4 Hz, 2H); 5.40 (d, J = 3.0 Hz, 1H); 3.97-3.83 (m, 1H); 3.70 (d, J = 1.0 Hz, 1H); 2.33 (s, 3H); 1.28 (s, 9H); 0.97 (d, J = 6.7 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 169.0; 167.4; 142.0; 138.0; 136.2; 136.0; 134.2; 133.0; 129.0; 128.5; 128.1; 127.8; 127.4; 125.9; 81.4; 68.5; 51.0; 26.8; 20.5; 18.3.

ee = 98%;  $[\alpha]_D^{25}$ : -17 (c = 0.6; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 5/95, flow rate 0.7 mL/min ( $\lambda = 254.4$  nm),  $\tau_{syn}$ : 26.7 min (2*R*,3*S*) and 72.7 min (2*S*,3*R*).



(2S,3R)-tert-Butyl-2-[bis(4-fluorophenyl)methyleneamino]-3-(4-methylphenyl-



**sulfonamido)butanoate** (6). Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) with 1a (68.9 mg, 0.19 mmol) in THF (2 mL), at -20 °C for 17 h, afforded, after flash chromatography (*n*-hexane-EtOAc 6:1), *syn*-6 as a light yellow solid; yield: 58.2 mg

(74%, *syn/anti* = >98:<2); m.p: 163–164 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.67 (d, J = 8.3 Hz, 2H); 7.56-7.48 (m, 2H); 7.17 (d, J = 7.7 Hz, 2H); 7.06-6.90 (m, 6H); 5.42 (d, J = 9.4 Hz, 1H); 3.97-3.84 (m, 1H); 3.71 (d, J = 3.0 Hz, 1H); 2.33 (s, 3H); 1.28 (s, 9H); 0.97 (d, J = 6.6 Hz, 1H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 170.2; 168.6; 164.5 (d, <sup>1</sup> $J_{C-F} = 250.5$  Hz); 162.8 (d, <sup>1</sup> $J_{C-F} = 247.5$  Hz); 143.0; 139.0; 135.05 (d, <sup>4</sup> $J_{C-F} = 3.0$  Hz); 131.7 (d, <sup>4</sup> $J_{C-F} = 3.7$  Hz); 130.9 (d, <sup>3</sup> $J_{C-F} = 8.2$  Hz); 129.5; 129.4 (d, <sup>3</sup> $J_{C-F} = 8.2$  Hz); 126.9; 115.92 (d, <sup>2</sup> $J_{C-F} = 21.3$  Hz); 115.2 (d, <sup>2</sup> $J_{C-F} = 21.8$  Hz); 82.3; 69.4; 52.0; 27.8; 21.5; 19.4. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): -111.3; -109.4; HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>28</sub>H<sub>31</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 529.1967 Found: 529.1952.

ee = >99%;  $[\alpha]_D^{25}$ : -35 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 4/96, flow rate 1.0 mL/min ( $\lambda = 254.4$  nm),  $\tau_{syn}$ : 19.8 min (2*R*,3*S*) and 50.1 min (2*S*,3*R*).



#### (2S,3R)-tert-Butyl-2-{[bis(4-fluorophenyl)methylene]amino}-3-(4-nitrophenyl-



sulfonamido)butanoate (8). Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) with 4-nitro-*N*-(1-tosylethyl)benzenesulfonamide (1c) (75.0 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 17 h, afforded, after flash chromatography (*n*-hexane-EtOAc

7:1), *syn*-**8** as a light yellow oil; yield: 26.7 mg (32%, *syn/anti* = >98:<2). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 8.27-8.21 (m, 2H); 8.06-7.97 (m, 2H); 7.56-7.47 (m, 2H); 7.11-6.91 (m, 6H); 5.73 (d, *J* = 9.1 Hz, 1H); 4.09-3.94 (m, 1H); 3.71 (d, *J* = 2.6 Hz, 1H); 1.25 (s, 9H); 1.03-0.99 (d, *J* = 6.6 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 170.8; 168.4; 164.6 (d, <sup>*1*</sup>*J*<sub>*C*-*F*</sub> = 251.2 Hz); 162.8 (d, <sup>*1*</sup>*J*<sub>*C*-*F*</sub> = 246.7 Hz); 149.8; 147.8; 134.84 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 3.0 Hz); 131.6 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 3.7 Hz); 130.9 (d, <sup>3</sup>*J*<sub>*C*-*F*</sub> = 9.0 Hz); 129.3 (d, <sup>3</sup>*J*<sub>*C*-*F*</sub> = 8.3 Hz); 128.1; 124.2; 116.0 (d, <sup>2</sup>*J*<sub>*C*-*F*</sub> = 21.0 Hz); 115.3 (d, <sup>2</sup>*J*<sub>*C*-*F*</sup> = 21.7 Hz); 82.5; 69.2; 52.3; 25.3; 19.9. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): -110.9.; -109.0. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>27</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub>F<sub>2</sub>S: 560.1687; Found: 560.1680; (M<sup>+</sup>+2H-<sup>t</sup>Bu): calculated C<sub>23</sub>H<sub>20</sub>N<sub>3</sub>O<sub>6</sub>F<sub>2</sub>S: 504.1035; Found: 504.1030.</sub>

ee = 97%;  $[\alpha]_D^{25}$ : -12 (c = 0.3; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak IA, *i*-PrOH/hexane 10/90, flow rate 0.7 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  <sub>syn</sub>: 23.9 min (2*R*,3*S*), 49.4 (2*S*,3*R*).



#### (2S,3R)-tert-Butyl-2-{[bis(4-fluorophenyl)methylene]amino}-3-(naphthalene-2-



**sulfonamido)butanoate** (9). Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)-methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) with *N*-(1-tosylethyl)naphthalene-2-sulfonamide (1d) (75.9 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 17 h, afforded, after flash chromatography (*n*-hexane-EtOAc 7:1), *syn-9* as a

colourless oil; yield: 45.5 mg (54%, *syn/anti* = >98:<2). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 8.56 (d, J = 8.5 Hz, 1H); 8.2 (dd, J = 7.3 Hz, J = 1.1 Hz, 1H); 7.96 (d, J = 8.3 Hz, 1H); 7.85 (d, J = 7.9 Hz, 1H); 7.65-7.56 (m, 1H); 7.55-7.50 (m, 1H); 7.49-7.38 (m, 3H); 7.03-6.85 (m, 6H); 5.74 (d, J = 9.2 Hz, 1H); 3.85-3.80 (m, 1H); 3.61 (d, J = 2.8 Hz, 1H); 1.20 (s, 9H); 0.84 (d, J = 6.8 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 170.1; 168.53; 164.5 (d, <sup>*1*</sup> $J_{C-F} = 250.5$  Hz); 162.8 (d, <sup>*1*</sup> $J_{C-F} = 247.5$  Hz); 136.62; 135.05 (d, <sup>*4*</sup> $J_{C-F} = 3.0$  Hz); 134.3; 133.9; 131.6 (d, <sup>*4*</sup> $J_{C-F} = 3.7$  Hz); 130.8 (d, <sup>*3*</sup> $J_{C-F} = 8.2$  Hz); 129.3 (d, <sup>*3*</sup> $J_{C-F} = 8.2$  Hz); 129.0; 128.9; 128.2; 128.1; 126.7; 124.6; 124.2; 115.8 (d, <sup>*2*</sup> $J_{C-F} = 21.3$  Hz); 115.1 (d, <sup>*2*</sup> $J_{C-F} = 21.3$  Hz); 82.4; 69.3; 52.2; 27.8; 18.9. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): -111.3; -109.4. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>31</sub>H<sub>31</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 565.1967; Found: 565.1986; (M<sup>+</sup>+2H-<sup>*t*</sup>Bu): calculated C<sub>27</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 509.1341; Found: 509.1334.

ee = 97%;  $[\alpha]_D^{25}$ : -30 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 5/95, flow rate 0.7 mL/min ( $\lambda = 254.4$  nm),  $\tau_{syn}$ : 21.6 min (2*R*,3*S*), 44.7 (2*S*,3*R*).



#### (2S,3R)-tert-Butyl-2-{[bis(4-fluorophenyl)methylene]amino}-3-(4-methylphenyl-



sulfonamido)pentanoate (20). Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)-methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) with 4-methyl-N-(1-tosylpropyl)benzenesulfonamide (10) (71.6 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 23 h, afforded, after flash chromatography (*n*-hexane-EtOAc 7:1), *syn*-20 as a

light yellow solid; yield: 72.9 mg (90%, *syn/anti* = 99:1); m.p: 151.0–152.3 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.71-7.64 (m, 2H); 7.55-7.47 (m, 2H); 7.16 (d, *J* = 8.1 Hz, 2H); 7.07-6.90 (m, 6H); 5.50 (d, *J* = 9.4 Hz, 1H); 3.85-3.79 (m, 1H); 3.77-3.62 (m, 1H); 2.33 (s, 3H); 1.51-1.38 (m, 2H); 1.28 (s, 9H); 0.60 (t, *J* = 7.3 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 170.0; 169.1; 164.5 (d, <sup>1</sup>*J*<sub>C-F</sub> = 249.7 Hz); 162.8 (d,

 ${}^{1}J_{C-F} = 247.5 \text{ Hz}$ ; 142.9; 139.4; 135.1 (d,  ${}^{4}J_{C-F} = 3.0 \text{ Hz}$ ); 131.8 (d,  ${}^{4}J_{C-F} = 3.7 \text{ Hz}$ ); 130.8 (d,  ${}^{3}J_{C-F} = 9.0$  Hz); 129.5; 129.4 (d,  ${}^{3}J_{C-F} = 8.2$  Hz); 126.8; 115.7 (d,  ${}^{2}J_{C-F} = 21.3$ Hz); 115.2 (d,  ${}^{2}J_{C-F} = 21.3$  Hz); 82.3; 66.7; 57.9; 27.9; 26.1; 21.4; 10.3.  ${}^{19}$ F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): -111.2; -109.5. HRMS (ESI<sup>+</sup>) (M<sup>+</sup> + H): calculated C<sub>29</sub>H<sub>33</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 543.2123; Found: 543.2111.

ee = 99%;  $[\alpha]_D^{25}$ : - 43 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak IA, *i*-PrOH/hexane 8/92, flow rate 0.8 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  syn: 15.0 min (2*R*,3*S*) and 21.4 min (2*S*,3*R*).



(2S,3R)-tert-Butyl-2-{[bis(4-fluorophenyl])methylene]amino}-3-(4-methylphenyl-



sulfonamido)-hexanoate (21). Following the general procedure, the reaction of tert-butyl 2-[bis(4-fluorophenyl)methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) with 4methyl-N-(1-tosylbutyl)benzenesulfonamide (11) (74.4 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 23 h, afforded, after flash chromatography (n-hexane-EtOAct 7:1), svn-21 as a colourless oil; yield: 73.4 mg (88 %, syn/anti = 96:4). <sup>1</sup>H-

NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.71-7.63 (m, 2H); 7.55-7.46 (m, 2H); 7.16 (d, J =7.9 Hz, 2H); 7.07-6.91 (m, 6H); 5.44 (d, J = 9.3 Hz, 1H); 3.84-3.78 (m, 1H); 3.78-3.69 (m, 1H); 2.33 (s, 3H); 1.45-1.39 (m, 1H); 1,28 (s, 9H); 1.22-1.16 (m, 1H); 0.84-0.75 (m, 2H); 0.70 (t, J = 7.2 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 169.9; 169.1; 164.5 (d,  ${}^{1}J_{C-F} = 249.7$  Hz); 162.8 (d,  ${}^{1}J_{C-F} = 247.5$  Hz); 142.9; 139.3; 135.1 (d,  ${}^{4}J_{C-F} = 3.0$ Hz); 131.8 (d,  ${}^{4}J_{C-F} = 3.0$  Hz); 130.8 (d,  ${}^{3}J_{C-F} = 8.2$  Hz); 129.4; 129.3 (d,  ${}^{3}J_{C-F} = 8.2$ Hz); 126.7; 115.8 (d,  ${}^{2}J_{CF} = 21.3$  Hz); 115.2 (d,  ${}^{2}J_{CF} = 21.3$  Hz); 82.3; 67.1; 56.1; 35.1; 27.9; 21.4; 18.9; 13.7. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>), δ (ppm): -111.2; -109.5. HRMS  $(ESI^{+})$  (M<sup>+</sup>+H): calculated C<sub>30</sub>H<sub>35</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 557.2280; Found: 543.2278. ee = 96%;  $[\alpha]_D^{25}$ : -31 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak IA, *i*-PrOH/hexane

10/90, flow rate 0.7 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  svn: 17.02 min (2S,3R), 26.9 min (2R,3S).







**methylphenylsulfonamido)decanoate (22).** Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)methyleneamino]acetate **(2d)** (49.7 mg, 0.15 mmol) with 4-methyl-*N*-(1-tosyloctyl)benzene-sulfonamide **(12)** (85.3 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 24 h, afforded, after flash chromatography

(*n*-hexane-EtOAct 7:1), *syn*-**22** as a light yellow oil; yield: 73.5 mg (80%, *syn/anti* = 98:2). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>), δ (ppm): 7.71-7.63 (m, 2H); 7.56- 7.48 (m, 2H); 7.16 (d, J = 8.1 Hz, 2H); 7.06-6.89 (m, 6H); 5.48 (d, J = 9.6 Hz, 1H); 3.81 (d, J = 2.6 Hz, 1H); 3.78-3.68 (m, 1H); 2.33 (s, 3H); 1.49-1.31 (m, 2H); 1.29 (s, 9H); 1.23-1.12 (m, 2H); 1.11-0.98 (m, 7H); 0.91-0.83 (m, 1H); 0.78 (t, J = 6.9 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>), δ (ppm): 169.9; 169.1; 164.5 (d, <sup>1</sup> $J_{C-F} = 250.5$  Hz); 162.8 (d, <sup>1</sup> $J_{C-F} = 247.5$  Hz); 142.9; 139.3; 134.1 (d, <sup>4</sup> $J_{C-F} = 3.0$  Hz); 131.8 (d, <sup>4</sup> $J_{C-F} = 3.7$  Hz); 130.9 (d, <sup>3</sup> $J_{C-F} = 9.0$  Hz); 129.4; 129.4 (d, <sup>3</sup> $J_{C-F} = 8.2$  Hz); 126.9; 115.8 (d, <sup>2</sup> $J_{C-F} = 21.9$  Hz); 115.2 (d, <sup>2</sup> $J_{C-F} = 21.3$  Hz); 82.3; 67.1; 56.5; 32.9; 31.6; 29.1; 29.0; 27.9; 25.7; 22.6; 21.4; 14.0. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>), δ (ppm): -111.2; -109.5. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>34</sub>H<sub>43</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 613.2906; Found: 613.2906.

ee = 99%;  $[\alpha]_D^{25}$ : -30 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak IA, *i*-PrOH/hexane 3/97, flow rate 0.7 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  <sub>syn</sub>: 27.5 min (2*R*,3*S*) and 34.9 min (2*S*,3*R*).



(2S,3R)-tert-Butyl-2-{[bis(4-fluorophenyl)methylene]amino}-5-methyl-3-(4-



**methylphenylsulfonamido) hexanoate (23).** Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)methyleneamino]acetate **(2d)** (49.7 mg, 0.15 mmol) with 4-methyl-N-(3-methyl-1-tosylbutyl)-benzenesulfonamide **(13)** (77.1 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 24 h, afforded, after flash

chromatography (*n*-hexane-EtOAct 7:1), *syn*-**23** as a light yellow solid; yield: 70.2 mg (80%, *syn/anti* = 96:4); m.p: 114.3–115.1 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.70-7.62 (m, 2H); 7.56-7.47 (m, 2H); 7.16 (d, *J* = 8.1 Hz, 2H); 7.06-6.89 (m, 6H); 5.42 (d, *J* = 9.4 Hz, 1H); 3.83-3.78 (m, 1H); 3.78-3.73 (m, 1H); 2.33 (s, 3H); 1.29 (s, 9H); 1.25-1.17 (m, 2H); 0.82-0.77 (m, 1H); 0.73 (d, *J* = 6.2 Hz, 3H); 0.67 (d, *J* = 6.2 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 169.9; 169.1; 164.5 (d, <sup>*1*</sup>*J*<sub>*C*-*F*</sub> = 250.5 Hz); 162.8 (d, <sup>*1*</sup>*J*<sub>*C*-*F*</sub> = 247.5 Hz); 142.9; 139.2; 135.1 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 3.0 Hz); 131.8 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 21.3 Hz); 115.2 (d, <sup>*2*</sup>*J*<sub>*C*-*F*</sub> = 21.9 Hz); 82.3; 67.1; 54.6; 41.9; 27.9; 24.4; 22.5; 22.3; 21.4. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): -111.2; -109.5. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>31</sub>H<sub>37</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 571.2436; Found: 571.2457.

ee = 99%;  $[\alpha]_D^{25}$ : -33 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak IA, *i*-PrOH/hexane 3/97, flow rate 0.7 mL/min ( $\lambda = 254.4$  nm),  $\tau_{syn}$ : 34.8 min (2*R*,3*S*) and 41.2 min (2*S*,3*R*).



#### (2S,3R)-tert-Butyl-2-{[bis(4-fluorophenyl)methylene]amino}-4-ethyl-3-(4-



**methylphenylsulfonamido) hexanoate (24).** Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)methyleneamino]acetate **(2d)** (49.7 mg, 0.15 mmol) with N-(2-ethyl-1-tosylbutyl)-4-methylbenzenesulfonamide **(14)** (79.9 mg, 0.19 mmol) in THF (2 mL) at rt for 18 h, afforded, after flash

chromatography (*n*-hexane-EtOAct 7:1), *syn*-**24** as a light yellow oil; yield: 60.0 mg (70%, *syn/anti* = >99:<1). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.72 (d, *J* = 8.1 Hz, 2H); 7.57-7.44 (m, 2H); 7.21 (d, *J* = 7.9 Hz, 2H); 7.12-6.90 (m, 6H); 5.91 (d, *J* = 8.5 Hz, 1H); 4.11-3.98 (m, 1H); 3.86-3.75 (m, 1H); 3.09 (s, 3H); 1.42-1.29 (m, 1H); 1.26 (s, 9H); 1.23-1.04 (m, 2H); 0.92-0.76 (m, 2H); 0.72 (t, *J* = 7.0 Hz, 3H); 0.62 (t, *J* = 6.6 Hz, 3H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 169.9; 169.6; 164.5 (d, <sup>*I*</sup>*J*<sub>*C*-*F*</sub> = 249.7 Hz); 162.8 (d, <sup>*I*</sup>*J*<sub>*C*-*F*</sub> = 9.0 Hz); 142.7; 139.3; 135.0 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 3.0 Hz); 132.1 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 21.7 Hz); 115.6 (d, <sup>2</sup>*J*<sub>*C*-*F*</sup> = 21.7 Hz); 82.2; 65.0; 56.8; 45.5; 27.7; 22.6; 22.1; 21.4; 11.9; 11.6. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 111.1; -109.4. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>32</sub>H<sub>39</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 585.2593; Found: 585.2567.</sub>

ee = 97%;  $[\alpha]_D^{25}$ : -44 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak IA, *i*-PrOH/hexane 3/97, flow rate 0.7 mL/min ( $\lambda = 254.4$  nm),  $\tau_{syn}$ : 33.4 min (2*S*,3*R*), 42.2 (2*R*,3*S*).



#### (2S,3R)-tert-Butyl-3-cyclopentyl-2-(diphenylmethyleneamino)-3-(4-methylphenyl-



sulfonamido)propanoate (25). Following the general procedure, the reaction of *tert*-butyl 2-(diphenylmethylene-amino)acetate (2b) (44.3 mg, 0.15 mmol) and *N*-[cyclopentyl-(tosyl)methyl]-4-methylbenzenesulfonamide (15) (79.5 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 17 h, afforded, after flash chromatography (*n*-hexane-EtOAct 6:1), *syn*-25 as a white

solid; yield: 68.2 mg (83%, *syn/anti* = >99:<1); m.p: 62–63 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.80 (d, *J* = 8.3 Hz, 2H); 7.68-7.59 (m, 2H); 7.48-7.40 (m, 4H); 7.40-7.34 (d, *J* = 7.5 Hz, 2H); 7.27-7.22 (m, 2H); 7.15-7.05 (m, 2H); 5.92 (d, *J* = 8.8 Hz, 1H); 3.98 (s, 1H); 4.05-3.90 (m, 1H); 2.41 (s, 3H); 1.98-1.80 (m, 1H); 1.60-1.45 (m, 3H); 1.45-1.35 (m, 2H); 1.39 (s, 9H); 1.24-1.01 (m, 2H); 0.95-0.86 (m, 1H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 171.8; 169.3; 142.5; 139.9; 139.0; 130.7; 129.3; 128.9; 128.5; 128.1; 127.4; 126.9; 82.1; 67.9; 60.6; 44.6; 30.1; 29.5; 27.9; 25.11; 24.9; 21.5. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>32</sub>H<sub>39</sub>N<sub>2</sub>O<sub>4</sub>S: 547.2625; Found: 547.2623 *ee* = >99 %; [ $\alpha$ ]<sub>D</sub><sup>25</sup>: -18 (*c* = 0.5; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane

3/97, flow rate 1.0 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  syn: 24.5 min (2S,3R), 44.6 min (2R,3S).



#### (2S,3R)-tert-Butyl-3-cyclohexyl-2-(diphenylmethyleneamino)-3-(4-methylphenyl-



sulfonamido)-propanoate (26). Following the general procedure, the reaction of *tert*-butyl 2-(diphenylmethylene-amino)acetate (2b) (44.3 mg, 0.15 mmol) with *N*-[cyclohexyl(tosyl)methyl]-4-methylbenzenesulfonamide (16) (82.2 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 17 h, afforded, after flash chromatography (*n*-hexane-EtOAc 6:1),

*syn*-**26b** as a white solid; yield: 67.3 mg (80%, *syn/anti* = 98:2); m.p: 58–60 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.70 (d, J = 8.2 Hz, 2H); 7.52 (d, J = 8.5 Hz, 2H); ); 7.39-7.25 (m, 4H); 7.36-7.18 (m, 2H); 7.18-7.11 (m, 2H); 7.05-6.90 (m, 2H); 5.90 (d, J = 8.7 Hz, 1H); 3.78 (dd, J = 1.6 Hz, J = 6.72 Hz, 1H); 2.30 (s, 3H); 1.60-1.42 (m, 5H); 1.24 (s, 9H); 1.10-0.61 (m, 6H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 171.3; 169.6; 142.6; 139.6; 138.9; 136.6; 130.7; 129.3; 128.9; 128.5; 128.1; 127.2; 126.9; 81.9; 65.7; 60.6; 41.8; 29.7; 29.1; 27.8; 26.3; 26.3; 26.2; 21.4. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>33</sub>H<sub>41</sub>N<sub>2</sub>O<sub>4</sub>S: 561.2781. Found: 561.2783.

ee = 97%;  $[\alpha]_D^{25}$ : -40 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 3/97, flow rate 0.7 mL/min ( $\lambda = 254.4$  nm),  $\tau_{syn}$ : 38.1 min (2*S*,3*R*) and 66.1 min(2*R*,3*S*).



#### (2S,3R)-tert-Butyl-2-{[bis(4-fluorophenyl)methylene]amino}-3-(4-methylphenyl-



sulfonamido)-5-phenylpentanoate (27). Following the general procedure, the reaction of *tert*-butyl-2-[bis(4-fluorophenyl)methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) and 4-methyl-N-(3-phenyl-1-tosylpropyl)-benzenesulfonamide (17) (86.5 mg, 0.19 mmol) in THF (3 mL) at -20 °C for 18 h, afforded, after flash

chromatography (n-hexane-EtOAc 7:1), syn-27 as a light yellow solid; yield: 53.2 mg

(57%, *syn/anti* = 96:4); m.p: 55.4–56.0 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>), δ (ppm): 7.61 (d, J = 7.9 Hz, 2H); 7.53-7.44 (m, 2H); 7.21-7.12 (m, 4H); 7.11-6.85 (m, 9H); 5.54 (d, J = 9.4 Hz, 1H); 3.86 (d, J = 2.4 Hz, 1H); 3.75-3.68 (m, 1H); 2.44-2.33 (m, 1H); 2.33 (s, 3H); 2.30-2.22 (m, 1H); 1.90-1.75 (m, 1H); 1.74-1.60 (m, 1H); 1.28 (s, 9H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>), δ (ppm): 170.1; 169.0; 164.6 (d,  ${}^{1}J_{C-F} = 250.5$  Hz); 162.8 (d,  ${}^{1}J_{C-F} = 247.5$  Hz); 143.0; 140.9; 139.0; 135.1 (d,  ${}^{4}J_{C-F} = 2.2$  Hz); 131.7 (d,  ${}^{4}J_{C-F} = 3.7$  Hz); 130.9 (d,  ${}^{3}J_{C-F} = 9.0$  Hz); 129.5; 129.4 (d,  ${}^{3}J_{C-F} = 7.5$  Hz); 128.4; 128.3; 126.9; 126.0; 116.0 (d,  ${}^{2}J_{C-F} = 21.3$  Hz); 115.2 (d,  ${}^{2}J_{C-F} = 21.3$  Hz); 82.4; 67.0; 55.9; 34.3; 32.0; 27.9; 21.4. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>), δ (ppm): -111.1; -109.4. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>35</sub>H<sub>37</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 619.2436; Found: 619.2458.

ee = 96%;  $[\alpha]_D^{25}$ : -37 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 15/85, flow rate 0.5 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  <sub>syn</sub>: 17.4 min (2*R*,3*S*), 21.4 (2*S*,3*R*).



(2S,3R)-tert-Butyl-2-{[bis(4-fluorophenyl)methylene]amino}-3-(4-methylphenyl-



sulfonamido)non-6-enoate (28). Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) with 4-methyl-N-(1-tosylhept-4-enyl)benzenesulfonamide (18) (85.2 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 20 h, afforded, after

flash chromatography (*n*-hexane-EtOAc 7:1), *syn*-**28** as a colourless oil; yield: 70.4 mg (78%, *syn/anti* = 90:10). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.71-7.64 (m, 2H); 7.57-7.48 (m, 2H); 7.22-7.14 (m, 2H); 7.09-6.92 (m, 6H); 5.49 (d, *J* = 9.4 Hz, 1H); 5.28-5.15 (m, 1H); 5.13-4.98 (m, 1H); 3.82 (d, *J* = 2.6 Hz, 1H); 3.81-3.72 (m, 1H); 2.33 (s, 3H); 1.80-1.60 (m, 4H); 1.47-1.33 (m, 2H); 1.29 (s, 9H); 0.78 (t, *J* = 7.5 Hz, 3H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 170.0; 169.0; 164.5 (d, <sup>*I*</sup>*J*<sub>*C*-*F*</sub> = 249.7 Hz); 162.9 (d, <sup>*I*</sup>*J*<sub>*C*-*F*</sub> = 247.5 Hz); 142.9; 139.3; 135.1 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 3.0 Hz); 132.6; 131.8 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> =

3.7 Hz); 130.9 (d,  ${}^{3}J_{C-F} = 9.0$  Hz); 129.5; 129.4 (d,  ${}^{3}J_{C-F} = 9.0$  Hz); 127.2; 126.9; 115.8 (d,  ${}^{2}J_{C-F} = 21.3$  Hz); 115.2 (d,  ${}^{2}J_{C-F} = 21.3$  Hz); 82.3; 66.9; 56.0; 32.8; 27.9; 23.5; 21.4; 20.5; 14.2.  ${}^{19}$ F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): -111.2; -109.5. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>33</sub>H<sub>39</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 597.2593; Found: 597.2601.

ee = 99%;  $[\alpha]_D^{25}$ : -10 (c = 0.3; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 10/90, flow rate 0.7 mL/min ( $\lambda = 254.4$  nm),  $\tau_{syn}$ : 12.0 min (2*R*,3*S*), 16.4 (2*S*,3*R*).



(2S,3R)-tert-Butyl-4-(benzyloxy)-2-{[bis(4-fluorophenyl)methylene]amino}-3-(4-



methylphenylsulfonamido) butanoate (29). Following the general procedure, the reaction of *tert*butyl 2-[bis(4-fluorophenyl)methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) and N-[2-(benzyloxy)-1tosylethyl]-4-methylbenzenesulfonamide (19) (89.62 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 19 h,

afforded, after flash chromatography (*n*-hexane-EtOAc 7:1), *syn*-**29** as a light yellow oil; yield: 46.7 mg (50%, *syn/anti* = 95:5). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.72-7.66 (m, 2H); 7.54-7.46 (m, 2H); 7.24-7.19 (m, 3H); 7.14 (d, *J* = 8.1 Hz, 2H); 7.08-7.02 (m, 2H); 6.98-6.84 (m, 6H); 5.59 (d, *J* = 9.1 Hz, 1H); 4.33-4.20 (m, 2H); 4.16-4.12 (m, 1H); 4.11-4.03 (m, 1H); 3.53-3.42 (m, 1H); 3.21 (t, *J* = 9.1 Hz, 1H); 2.31 (s, 3H); 1.21 (s, 9H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 170.8; 168.8; 164.5 (d, <sup>*1*</sup>*J*<sub>*C*-*F*</sub> = 247.5 Hz); 143.0; 138.9; 137.6; 135.1 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 3.0 Hz); 131.67 (d, <sup>*4*</sup>*J*<sub>*C*-*F*</sub> = 3.7 Hz); 130.9 (d, <sup>3</sup>*J*<sub>*C*-*F*</sub> = 9.0 Hz); 129.5 (d, <sup>3</sup>*J*<sub>*C*-*F*</sup> = 7.5 Hz); 129.5; 128.3; 127.7; 127.5; 126.9; 115.6 (d, <sup>2</sup>*J*<sub>*C*-*F*</sup> = 21.3 Hz); 115.1 (d, <sup>2</sup>*J*<sub>*C*-*F*</sup> = 21.3 Hz); 82.2; 73.1; 69.8; 64.7; 54.8; 27.7; 21.4. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): -111.6; -109.5. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>35</sub>H<sub>37</sub>N<sub>2</sub>O<sub>5</sub>F<sub>2</sub>S: 635.2385; Found: 635.2389. *ee* = 93%; [ $\alpha$ ]<sub>D</sub><sup>25</sup>: -30 (*c* = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 15/85, flow rate 0.5 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  <sub>syn</sub>: 16.2 min (2*R*,3*S*), 36.2 (2*S*,3*R*).</sub></sub></sub>



#### (2S)-tert-Butyl-2-[bis(4-fluorophenyl)Methyleneamino]-3-(4-methylphenyl-



sulfonamido)propanoate (31). Following the general procedure, the reaction of *tert*-butyl 2-[bis(4-fluorophenyl)-methyleneamino]acetate (2d) (49.7 mg, 0.15 mmol) with 4-methyl-*N*-(tosylmethyl)benzenesulfonamide (30) (66.2 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 12 h, afforded, after flash chromatography (*n*-hexane-EtOAc 6:1), *syn*-31 as a light yellow

solid; yield: 61.5 mg (80%); m.p: 59-60 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.61 (d, J = 8.3 Hz, 2H); 7.52-7.43 (m, 2H); 7.26 (d, J = 7.4 Hz, 2H); 7.05 (d, J = 7.0 Hz, 4H); 6.97-6.87 (m, 2H); 4.96 (t, J = 6.4 Hz, 1H); 3.98 (t, J = 5.8 Hz, 1H); 3.29 (t, J = 6.2 Hz, 2H); 2.33 (s, 3H); 1.31 (s, 9H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 170.6; 168.8; 164.5 (d, <sup>1</sup> $J_{C-F} = 250.5$  Hz); 162.9 (d, <sup>1</sup> $J_{C-F} = 247.5$  Hz); 143.4; 137.1; 135.2 (d, <sup>4</sup> $J_{C-F} = 3.0$  Hz); 131.4 (d, <sup>4</sup> $J_{C-F} = 3.7$  Hz); 130.9 (d, <sup>3</sup> $J_{C-F} = 8.2$  Hz); 129.7 (d, <sup>3</sup> $J_{C-F} = 7.5$  Hz); 129.7; 127.0; 115.8 (d, <sup>2</sup> $J_{C-F} = 21.7$  Hz); 115.2 (d, <sup>2</sup> $J_{C-F} = 21.8$  Hz); 82.3; 64.8; 45.6; 27.9; 21.5. <sup>19</sup>F-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): -109.4; -111.3. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>27</sub>H<sub>29</sub>N<sub>2</sub>O<sub>4</sub>F<sub>2</sub>S: 515.1810 Found: 515.1804

ee = 83%;  $[\alpha]_D^{25}$ : -35 (c = 1.0; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 4/96, flow rate 1.0 mL/min ( $\lambda = 254.4$  nm),  $\tau$ : 30.8 min (2*R*) and 47.2 min (2*S*).



# **1.3.** Selective *N*-deprotection of the Mannich adducts: conversion of 26 into the cyclic urea *trans*-33.<sup>5</sup>



#### (2S,3R)-tert-Butyl-2-amino-3-cyclohexyl-3-(4-methylphenylsulfonamido)-



**propanoate** (*syn-32*). To a solution of *syn-26* (272.6 mg, 0.48 mmol) in THF (4 mL), cooled to 0 °C, was added a 0.5 M aq solution of citric acid (2.0 mL). The mixture was allowed to reach rt and stirred for 2 h before it was extracted with Et<sub>2</sub>O (3 x 3 mL).

The combined organic phase was washed with water (3 x 3 mL), the aqueous phase was basified with saturated K<sub>2</sub>CO<sub>3</sub> solution and it was then extracted with EtOAc (3 x 3 mL). The organic phase was washed with brine (4 mL), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to afford syn-**32** as a colourless oil; yield: 175.0 mg (91%). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.66 (d, *J* = 9.0 Hz, 2H); 7.18 (d, *J* = 9.0 Hz, 2H); 5.27 (s, 1H); 3.44-3.36 (m, 1H); 3.33 (d, *J* = 3.0 Hz, 1H); 2.34 (s, 3H); 1.65-1.42 (m, 7H); 1.36 (s, 9H); 1.10-0.61 (m, 6H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 172.8; 143.0; 138.7; 129.4; 127.0; 82.2; 60.2; 54.7; 41.4; 29.8; 28.8; 27.9; 26.2; 26.1; 21.5. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>20</sub>H<sub>33</sub>N<sub>2</sub>O<sub>4</sub>S: 397.2155; Found: 397.2152; (M<sup>+</sup>+2H-<sup>t</sup>Bu): calculated C<sub>16</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>S: 341.1529; Found: 341.1525. [ $\alpha$ ]<sub>D</sub><sup>25</sup>: + 51 (*c* = 0.8; CHCl<sub>3</sub>).

<sup>5.</sup> For *cis*- and *trans*- assignment on imidazolidinones derived from α,β-diamino acid derivatives, see: S. H. Lee, J. Yoon, S. H. Chung, Y. S. Lee, *Tetrahedron*, 2001, **57**, 2139.

#### (4S,5R)-tert-Butyl 5-cyclohexyl-2-oxo-1-tosylimidazolidine-4-carboxylate (trans-A).



To a solution of *syn*-**32** (260.0 mg, 0.65 mmol) in dry  $CH_2Cl_2$  (4 mL), under inert atmosphere and cooled to 0 °C, was added dropwise a solution of triphosgene (486.1 mg, 1.64 mmol). The reaction mixture was stirred at 0 °C for 1 h before it was allowed to reach rt and stirred for further 2 h at rt. The mixture

was concentrated and the residue was purified by flash chromatography (*n*-hexane-EtOAc 2:1, stained with CAN) to afford *trans*-A as a light yellow solid; yield: 220.2 mg (80%); m.p: 73.1-75.0 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.79 (d, J = 6.0 Hz, 2H); 7.21 (d, J = 6.0 Hz, 2H); 5.77 (s, 1H); 4.24-4.20 (m, 1H); 3.70 (d, J = 3.0 Hz, 1H); 2.34 (s, 3H); 1.49-1.43 (m, 6H); 1.33 (s, 9H); 1.10-0.70 (m, 5H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 169.7; 155.2; 144.6; 136.2; 129.4; 127.9; 83.14; 64.7; 53.0; 41.6; 28.4; 27.8; 26.2; 25.9; 25.5; 25.3; 21.6. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>21</sub>H<sub>31</sub>N<sub>2</sub>O<sub>5</sub>S: 423.1948; Found: 423.1939; (M<sup>+</sup>+Na): calculated C<sub>21</sub>H<sub>30</sub>N<sub>2</sub>NaO<sub>5</sub>S: 445.1767; Found: 445.1762. [ $\alpha$ ]<sub>D</sub><sup>25</sup>: + 44 (c = 0.7; CHCl<sub>3</sub>).

#### (4S,5R)-tert-Butyl 5-cyclohexyl-2-oxoimidazolidine-4-carboxylate (trans-33). To a



solution of *trans*-A (45.0 mg, 0.106 mmol) in MeOH (5 mL) were added Mg turnings (52.0 mg, 2.13 mmol) and the reaction mixture was stirred under sonication at rt for 1 h. After that time the Mg was dissolved and the reaction mixture was filtered through Celite. The filtrate was concentrated and it was dissolved in

CH<sub>2</sub>Cl<sub>2</sub> (2 mL), then successively washed with a saturated aq. solution of K<sub>2</sub>CO<sub>3</sub> (3 x 2 mL) and brine. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to dryness. The residue was purified by flash chromatography (*n*-hexane-EtOAc 1:2, stained with ninhydrin) to afford *trans*-**33** as light brown solid; yield: 23.9 mg (84%); m.p: 156.1-157.8 °C. <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 5.48 (s, 1H); 4.98 (s, 1H); 3.82 (d, *J* = 3.0 Hz, 1H); 3.56-3.49 (m, 1H); 1.76-1.55 (m, 6H); 1.41 (s, 9H); 1.22-1.06 (m, 5H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 169.9; 161.2; 81.5; 59.7; 56.6; 41.8; 27.6; 27.1; 26.9; 25.3; 24.8; 24.7. HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>14</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub>: 269.1859; Found: 269.1870; (M<sup>+</sup>+Na): calculated C<sub>14</sub>H<sub>24</sub>N<sub>2</sub>NaO<sub>3</sub>: 291.1679; Found: 291.1668; (2M<sup>+</sup>+Na): calculated C<sub>28</sub>H<sub>48</sub>N<sub>4</sub>NaO<sub>6</sub>: 559.3472; Found: 559.3510. [ $\alpha$ ]<sub>D</sub><sup>25</sup>: +38 (*c* = 1.0; CHCl<sub>3</sub>).

# 2. Determination of the absolute and relative configuration of the Mannich products: preparation of compound 26'.



#### (2S,3R)-Methyl-3-cyclohexyl-2-(diphenylmethyleneamino)-3-(4-methylphenyl-

**sulfonamido)-propanoate (26').**<sup>6</sup> Following the general procedure, the reaction of 2-[(diphenylmethylene)amino]acetate **(2a)** (38.0 mg, 0.15 mmol) (44.3 mg, 0.15 mmol) with *N*-[cyclohexyl(tosyl)methyl]-4-methylbenzenesulfonamide **(16)** (82.2 mg, 0.19 mmol) in THF (2 mL) at -20 °C for 24 h, afforded, after flash chromatography (*n*-hexane-EtOAc 6:1), *syn*-**26**' as a yellow oil, yield: 50.5 mg (65%, *syn/anti* = 90:10). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>),  $\delta$  (ppm): 7.72-7.65 (d, *J* = 8.2 Hz, 2H); 7.57-7.51 (d, *J* = 7.1 Hz, 2H); 7.40-7.25 (m, 4H); 7.21-7.14 (m, 2H); 7.01-6.90 (m, 2H); 5.89 (d, *J* = 9.0 Hz, 1H); 4.05-3.98 (m, 1H); 3.68 (t, *J* = 7.9 Hz, 1H); 3.17 (s, 3H); 2.31 (s, 3H); 1.64-1.43 (m, 4H); 1.37-1.22 (m, 2H); 1.10-0.90 (m, 3H); 0.85-0.69 (m, 2H). HRMS (ESI<sup>+</sup>) (M<sup>+</sup>+H): calculated C<sub>30</sub>H<sub>35</sub>N<sub>2</sub>O<sub>4</sub>S: 519.2312. Found: 519.2323.

*ee* = 95%;  $[\alpha]_D^{25}$ : -38 (*c* = 0.9; CHCl<sub>3</sub>). HPLC: Daicel Chiralpak AD, *i*-PrOH/hexane 3/97, flow rate 0.7 mL/min ( $\lambda$ = 254.4 nm),  $\tau$  <sub>syn</sub>: 52.9 min (2*S*,3*R*) and 60.3 min(2*R*,3*S*).



The absolute and relative configuration of the Mannich products was determined by preparation of the known compound 26' (methyl ester derivative of product 26) and comparison of the NMR data and optical rotation with those described in the literature<sup>6</sup>

<sup>6.</sup> L. Bernardi, A. S. Gothelf, R. G. Hazell, K. A. JØrgensen, J. Org. Chem., 2003, 68, 2583. The configuration of all other products was assigned by analogy.

3. Base and solvent screening.

 $\{[\alpha]_D^{25} = -39 \ (c = 1.088, \text{CDCl}_3 \text{ for a } 92\% \text{ ee sample of } 26'\}^6$ . The configuration of all other product was assigned by analogy.

	F Ph	Ph <sup>™</sup> N <sup>™</sup> CO <sub>2</sub> Me + I 9 eq	HN <sup>-SO<sub>2</sub>Tol Fe Me<sup>-SO<sub>2</sub>Tol <u>Cu(C</u> 1.3 eq</sup></sup>	Base sulphos (10 mol %) H <sub>3</sub> CN)₄PF <sub>6</sub> (10 mol%) Solvent, rt, 5h	HI Me	$SO_2$ Tol CO <sub>2</sub> Me N Ph Ph
]	Entry	Base (1.2 eq)	Solvent	Conversion %	syn/anti	syn-ee %
	1	Cs <sub>2</sub> CO <sub>3</sub>	THF	89	88:12	93 <sup>*</sup>
	2	$Cs_2CO_3$ (1.5)	DCM	8	-	-
	3	$Cs_2CO_3$ (1.5)	Acetonitrile	53	79:21	-
	4	Cs <sub>2</sub> CO <sub>3</sub> (1.5)	Trifluorotoluene	53	87:13	93 <sup>*</sup>
	5	$Cs_2CO_3$ (1.5)	THF	95	88:12	90 <sup>*</sup>
Ì	6	Diisopropylamine	THF	55	73:27	-
	7	Triethylamine	THF	-	-	-
	8	Diisopropylethylami	ne THF	38	75:25	-
	9	Tetraethylammoniur bicarbonate	n THF	74	66:34	-
	10	K <sub>3</sub> PO <sub>4</sub>	THF	59	83:17	-
	11	(NBu <sub>4</sub> )PO <sub>4</sub> H <sub>2</sub>	THF	-	-	-

\* The enantiomeric excesses were measured only when both, the conversion and diastereoselectivity were good.

### 4. Chiral ligand screening.

Ph Ph $\sim$ CO <sub>2</sub> <sup>t</sup> Bu + 1.0 eq		HN <sup>_SO<sub>2</sub>Tol Cy SO<sub>2</sub>Tol 1.3 eq</sup>	Cs <sub>2</sub> CO <sub>3</sub> 1.2 <b>Ligand (X</b> mc Cu(CH <sub>3</sub> CN) <sub>4</sub> PF <sub>6</sub> (2 THF, rt, 5h	eq bl%) X mol%) Cչ	HN <sup>_SO</sup> 2Tol Cy ↓ CO2 <sup>/</sup> Bu N Ph Ph	
Entry	Ligand	% mmol	syn/anti <sup>a</sup>	Yield %	syn-ee %	
1	Fesulphos	10	90:10	73	89	
2	Fesulphos	5	87:13	52 <sup>*</sup>	-	
3	Fesulphos <i>p</i> -F	10	84:16	67	94	
4	Fesulphos <i>p</i> -OMe	10	86:14	74	88	
5	Mandyphos ( <i>R</i> , <i>S</i> )	10	-	23	-	
6	Josiphos ( $R, S_p$ )	10	92:8	54	93	

\* Conversion value from the crude <sup>1</sup>H-NMR.

\_

### 5. NMR spectra.

























































Electronic Supplementary Material (ESI) for Chemical Communications This journal is C The Royal Society of Chemistry 2012





Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2012







Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2012



Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2012





